Jefferies Reiterates Buy Rating on Tenet Healthcare (THC) After Labor Expense Remained Under Control

Jefferies analyst Brian Tanquilut reiterated a Buy rating and $120.00 price target on Tenet Healthcare (NYSE: THC) after the company reported above-consensus Q4 EBITDA and FY22 EBITDA guidance.

The analyst believes better-than-expected labor expenses, should drive a near term recovery in the stock, stating "Strong Guide Should Alleviate Investor Concerns, Especially on Labor,ASC/Growth Acceleration Thesis Still Holds, Valuation is Compelling With Path to $120. We believe THC shares should see a NT rebound as investor concerns about guidance and labor headwinds were addressed by mgmt's above-Street FY22 EBITDA outlook."

For an analyst ratings summary and ratings history on Tenet Healthcare click here. For more ratings news on Tenet Healthcare click here.

Shares of Tenet Healthcare closed at $70.00 yesterday.

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• MGM Resorts (MGM) PT Raised to $55 at Argus
• Benchmark Reiterates Hold Rating on VolitionRX (VNRX)